<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-152854</identifier>
<setSpec>1699-258X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Eficiency of different doses of rituximab in rheumatoid arthritis</dc:title>
<dc:description xml:lang="en">Objective. Evaluate the effectiveness, cost and safety of rituximab in patients with rheumatoid arthritis (RA) depending on the dose used. Material and methods. Retrospective observational study conducted on 52 patients with RA treated with at least one dose of rituximab for 135.3 patient-years were included. Three treatment groups were obtained: (G1) First course and following two 1g infusions separated by 15 days; (G2) First course 2 infusions of 1g followed by 2 infusions of 500mg; (G3) First course and followed by 2 infusions of 500mg separated by 15 days. Re-treatments were administered on-demand according to the clinical activity. The retention time (Log-Rank), retreats and adverse events rates (incidence rate ratio) and treatment costs per patient-month of rituximab were analysed by groups. Results. Group 2 showed a better cost-effectiveness ratio than group 1, as it was associated with a longer retention of rituximab (mean [95% CI] 65.7 [60.8 to 70.7] months vs 33.5 [22.7 to 44.3]; P&lt;.001) and a lower rate of severe adverse events with only a slight increase in the rate of retreatment (courses/patient-year [95% CI] 1.66 [1.39 to 1.93] vs. 1.01 [0.69 to 1.34]; P=.005), and in the costs (median/patient-month, &#128;484.89 vs. &#128;473.45). Although group 3 was &#128;41.20/patient-month cheaper than group 2, it was associated with a higher rate of re-treatments and shorter retention of rituximab (P&lt;.001). Conclusions. The use of full-dose rituximab at onset, followed by reduced doses in successive courses administered on-demand retreatment may be the most cost-effective option (AU)</dc:description>
<dc:creator>Irigoyen-Oyarzábal, María Victoria</dc:creator>
<dc:creator>Jiménez-Núñez, Francisco G</dc:creator>
<dc:creator>Fernández-Nebro, Antonio</dc:creator>
<dc:creator>Coret, Virginia</dc:creator>
<dc:creator>Manrique-Arija, Sara</dc:creator>
<dc:creator>Romero-Barco, Carmen M</dc:creator>
<dc:creator>Ureña-Garnica, Inmaculada</dc:creator>
<dc:creator>Mena-Vázquez, Natalia</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo. Evaluar la efectividad, seguridad y coste de rituximab en pacientes con artritis reumatoide (AR) dependiendo de la dosis utilizada. Material y métodos. Estudio observacional retrospectivo. Se incluyó a 52 pacientes con AR tratados al menos con una dosis de rituximab durante 135,3 pacientes-año. Se obtuvieron 3 grupos de tratamiento: G1, primer curso y siguientes de 2 infusiones de 1g separadas 15 días; G2, primer curso de 2 infusiones de 1g seguido por cursos de 2 infusiones de 500mg, y G3, primer curso y siguientes de 2 infusiones de 500mg separadas por 15 días. Los retratamientos fueron a demanda según la clínica. Se analizaron por grupos: el tiempo retención (Log-Rank), las tasas de retratamientos y de eventos adversos (razón de tasas de incidencia) y los costes del tratamiento por paciente-mes de rituximab. Resultados. El grupo 2 mostró una mejor relación coste-efectividad que el grupo 1 ya que se asoció a una mayor retención de rituximab (media [IC del 95%] 65,7 [60,8-70,7] meses vs. 33,5 [22,7-44,3]; p&lt;0,001) y una menor tasa de eventos adversos graves, con solo un ligero incremento de la tasa de retratamientos (cursos/paciente-año [IC del 95%] 1,66 [1,39-1,93] vs. 1,01 [0,69.-1,34]; p=0,005) y del coste (mediana/paciente-mes, 484,89 &#128; vs. 473,45 &#128;). Aunque el grupo 3 fue 41,20 &#128;/paciente-mes más económico que el grupo 2, se asoció a una mayor tasa de retratamientos y una menor retención de rituximab (p&lt;0,001). Conclusiones. El uso de rituximab a dosis completa al inicio seguido de dosis reducida en los sucesivos cursos administrados a demanda parece la opción más coste-efectiva (AU)</dc:description>
<dc:source>Reumatol. clín. (Barc.);12(3): 139-145, mayo-jun. 2016. ilus, tab</dc:source>
<dc:identifier>ibc-152854</dc:identifier>
<dc:title xml:lang="es">Eficiencia de diferentes dosis de rituximab en la artritis reumatoide</dc:title>
<dc:subject>^d55982^s22073</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d4365</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d22431</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d35251</dc:subject>
<dc:subject>^d30313^s22045</dc:subject>
<dc:subject>^d920^s22073</dc:subject>
<dc:subject>^d50303</dc:subject>
<dc:subject>^d29918</dc:subject>
<dc:subject>^d1178^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>201606</dc:date>
</metadata>
</record>
</ibecs-document>
